Cargando…

Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma

Background. Survival after surgery for pancreatic ductal adenocarcinoma (PDAC) remains poor, due to early recurrence (ER) of the disease. A global definition of ER is lacking and different cut-off values (6, 8, and 12 months) have been adopted. The aims of this study were to define the optimal cut-o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nappo, Gennaro, Donisi, Greta, Capretti, Giovanni, Ridolfi, Cristina, Pagnanelli, Michele, Nebbia, Martina, Bozzarelli, Silvia, Petitti, Tommasangelo, Gavazzi, Francesca, Zerbi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137113/ https://www.ncbi.nlm.nih.gov/pubmed/37185395 http://dx.doi.org/10.3390/curroncol30040282

Ejemplares similares

Enhanced Recovery After Pancreatic Surgery Does One Size Really Fit All? A Clinical Score to Predict the Failure of an Enhanced Recovery Protocol After Pancreaticoduodenectomy
por: Capretti, Giovanni, et al.
Publicado: (2020)

Borderline resectable pancreatic cancer: Certainties and controversies
por: Nappo, Gennaro, et al.
Publicado: (2021)

The Choice of the Most Appropriate Suture Threads for Pancreatic Anastomoses on the Basis of Their Mechanical Characteristics
por: Pagnanelli, Michele, et al.
Publicado: (2023)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

The Number of Metastatic Lymph Nodes is a Useful Predictive Factor for Recurrence after Surgery for Nonmetastatic Nonfunctional Neuroendocrine Neoplasm of the Pancreas
por: Capretti, G., et al.
Publicado: (2019)

Immune infiltrating cells in duodenal cancers
por: Donisi, G., et al.
Publicado: (2020)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
por: Balsano, Rita, et al.
Publicado: (2023)

International assessment and validation of the prognostic role of lymph node ratio in patients with resected pancreatic head ductal adenocarcinoma
por: Joliat, Gaëtan-Romain, et al.
Publicado: (2022)

Role of preoperative biliary stents, bile contamination and antibiotic prophylaxis in surgical site infections after pancreaticoduodenectomy
por: Gavazzi, Francesca, et al.
Publicado: (2016)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour—State of the Art and Perspectives
por: Nappo, Gennaro, et al.
Publicado: (2023)

The Role of Pathological Method and Clearance Definition for the Evaluation of Margin Status after Pancreatoduodenectomy for Periampullary Cancer. Results of a Multicenter Prospective Randomized Trial
por: Nappo, Gennaro, et al.
Publicado: (2021)

Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach
por: Palumbo, Diego, et al.
Publicado: (2021)

A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics
por: Tian, Ningzi, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Preoperative Prediction of Early Recurrence after Upfront Surgery in Pancreatic Ductal Adenocarcinoma by Integrating Deep Learning and Radiological Variables
por: Xiang, Fei, et al.
Publicado: (2023)

Prognostic impact of Ki‐67 proliferative index in resectable pancreatic ductal adenocarcinoma
por: Pergolini, I., et al.
Publicado: (2019)

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
por: Feigin, Michael E., et al.
Publicado: (2017)

Morphohistological Features of Pancreatic Stump Are the Main Determinant of Pancreatic Fistula after Pancreatoduodenectomy
por: Ridolfi, Cristina, et al.
Publicado: (2014)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
por: Laghi, Luigi, et al.
Publicado: (2012)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale
por: Arivazhagan, Sowbharnika, et al.
Publicado: (2021)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Microbiological Laboratory Diagnosis of Human Brucellosis: An Overview
por: Di Bonaventura, Giovanni, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma
por: Xia, Tao, et al.
Publicado: (2023)

Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence–Based Model
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008)

Pancreaticoduodenectomy of Pancreatic Ductal Adenocarcinoma in the Elderly
por: Kang, Chang Moo, et al.
Publicado: (2007)

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
por: Ottenhof, Niki A., et al.
Publicado: (2011)

Mast cells in pancreatic ductal adenocarcinoma
por: Chang, David Z.
Publicado: (2012)

Genetics and biology of pancreatic ductal adenocarcinoma
por: Ying, Haoqiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1eg3if54g78pku05leq97tastm